Literature DB >> 783214

Drug metabolism in liver disease.

L F Prescott, J A Forrest, K K Adjepon-Yamoah, N D Finlayson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 783214      PMCID： PMC1347183     

Source DB:  PubMed          Journal:  J Clin Pathol Suppl (R Coll Pathol)        ISSN： 0144-0330


× No keyword cloud information.
  23 in total

1.  RATE OF METABOLISM OF TOLBUTAMIDE IN TEST SUBJECTS WITH LIVER DISEASE OR WITH IMPAIRED RENAL FUNCTION.

Authors:  E NELSON
Journal:  Am J Med Sci       Date:  1964-12       Impact factor: 2.378

2.  Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease.

Authors:  R Groszmann; B Kotelanski; J N Cohn; I M Khatri
Journal:  Am J Med       Date:  1972-12       Impact factor: 4.965

3.  Changes in hepatic circulation at rest, during and after exercise in young males with infectious hepatitis compared with controls.

Authors:  P Lundbergh; T Strandell
Journal:  Acta Med Scand       Date:  1974-10

Review 4.  Factors affecting drug metabolism.

Authors:  J R Gillette
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

5.  Effect of carbon tetrachloride induced progressive liver damage on drug-metabolizing enzymes and cytochrome P-450 in rat liver.

Authors:  M Vorne; P Arvela
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1971

6.  Plasma-paracetamol half-life and hepatic necrosis in patients with paracetamol overdosage.

Authors:  L F Prescott; P Roscoe; N Wright; S S Brown
Journal:  Lancet       Date:  1971-03-13       Impact factor: 79.321

7.  Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy.

Authors:  A J Levi; S Sherlock; D Walker
Journal:  Lancet       Date:  1968-06-15       Impact factor: 79.321

8.  Determination of drug metabolizing enzymes in needle biopsies of human liver.

Authors:  B Schoene; R A Fleischmann; H Remmer; H F von Oldershausen
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

9.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059

10.  Metabolism of amylobarbitone in patients with chronic liver disease.

Authors:  G E Mawer; N E Miller; L A Turnberg
Journal:  Br J Pharmacol       Date:  1972-03       Impact factor: 8.739
View more
  3 in total

1.  Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma.

Authors:  Mario Uccello; Giulia Malaguarnera; Elisa M Pelligra; Antonio Biondi; Francesco Basile; Massimo Motta
Journal:  Indian J Med Paediatr Oncol       Date:  2011-04

Review 2.  Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan.

Authors:  P N Sidharta; A Treiber; J Dingemanse
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

3.  N-Acetylcysteine for Preventing Acetaminophen-Induced Liver Injury: A Comprehensive Review.

Authors:  Anna Licata; Maria Giovanna Minissale; Simona Stankevičiūtė; Judith Sanabria-Cabrera; Maria Isabel Lucena; Raul J Andrade; Piero Luigi Almasio
Journal:  Front Pharmacol       Date:  2022-08-10       Impact factor: 5.988
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.